Publication date: Available online 16 November 2026 Source: Genetics in Medicine Author(s): Giulia Del Medico, Anqing Zhang, Roopa Kanakatti Shankar, Kimberly Pitner, Niusha Shafaei, Raheem Seaforth, Andrew Dauber
Vosoritide Treatment in Children with Hypochondroplasia: Three-Year Results from a Phase 2 Extension Trial. // Genetics in Medicine. – URL: https://www.sciencedirect.com/science/article/pii/S1098360026011214?dgcid=rss_sd_all
Vosoritide Treatment in Children with Hypochondroplasia: Three-Year Results from a Phase 2 Extension Trial. Genetics in Medicine. https://www.sciencedirect.com/science/article/pii/S1098360026011214?dgcid=rss_sd_all
“Vosoritide Treatment in Children with Hypochondroplasia: Three-Year Results from a Phase 2 Extension Trial.” Genetics in Medicine.
@article{article46860,
title = {Vosoritide Treatment in Children with Hypochondroplasia: Three-Year Results from a Phase 2 Extension Trial},
journal = {Genetics in Medicine},
url = {https://www.sciencedirect.com/science/article/pii/S1098360026011214?dgcid=rss_sd_all}
}
ABSTRACT Very long‐chain acyl‐CoA dehydrogenase deficiency (VLCADD) is an autosomal recessive disorder of mitochondrial fatty acid β ‐oxidation caused by biallelic pathogenic variants in ACADVL. Its most severe form, the cardiomyopathic...